Contrast induced nephropathy medical therapy

Contrast Induced Nephropathy Microchapters
Home
Patient Information
Overview
Definition
Historical Perspective
Pathophysiology
Differentiating Contrast induced nephropathy from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Contrast induced nephropathy medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Contrast induced nephropathy medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Contrast induced nephropathy medical therapy
CDC on Contrast induced nephropathy medical therapy
Contrast induced nephropathy medical therapy in the news
Blogs on Contrast induced nephropathy medical therapy
Directions to Hospitals Treating Contrast induced nephropathy
Risk calculators and risk factors for Contrast induced nephropathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Overview

Management of CIN routinely includes the avoidance of substances that are toxic to the kidneys. Dialysis is rarely required for AKI following contrast administration, but occasionally patients will require dialysis in the acute setting. The indications for dialysis are the same as in other forms of AKI.